Oncology News

The FDA approved the initiation of an investigational device exemption clinical trial of a potential chemotherapy drug, Oncozene, for the treatment of hepatocellular carcinoma, according to a news release from CeloNova BioSciences.

Patients who underwent radiofrequency ablation for residual or recurring hepatocellular carcinoma after transarterial chemoembolization showed favorable overall survival rates, despite the frequency and early recurrence of tumors, according to new study data. 

Individuals with insufficient or deficient levels of serum 25-hydroxyvitamin D were at increased risk for hepatocellular carcinoma, according to study results.

Can-Fite BioPharma received a US patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular carcinoma, according to a news release.

There was no apparent relationship between exposure to sorafenib and safety and efficacy among patients with hepatocellular carcinoma or renal cell carcinoma, according to data presented at the European Society for Medical Oncology 2014 Congress in Madrid.

Candidates for liver transplant with hepatocellular carcinoma listed in the long waiting time regions had higher overall survival rates compared with patients in the short waiting time list regions, according to new study data.

Site-specific cancer patterns in type 1 diabetes largely follow incidence in patients with type 2 diabetes, but more minimal, and do not drastically differ from general populations, according to a presentation at the 50th European Association for the Study of Diabetes Annual Meeting.

An increased intake of vegetables, but not fruit, was associated with a lower risk for hepatocellular carcinoma, according to new study data.

Biostar Pharmaceuticals has filed an invention and creation patent application in China for oleanolic acid injection for the treatment of hepatitis B virus infection and liver cancer, according to a news release.

Patients with advanced hepatocellular carcinoma had an increased overall survival rate after treatment with a novel combination of etodolac and propranolol plus sorafenib compared with patients treated with only sorafenib, according to a news release.